A virosomal malaria Peptide vaccine elicits a longlasting sporozoite-inhibitory antibody response in a phase 1a clinical trail

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Okitsu, Shinji L ^a,f   Silvie, Olivier ^b,g   Westerfeld, Nicole ^c   Curcic, Marija ^a   Kammer, Andreas R ^c   Mueller, Markus S ^a   Sauerwein, Robert W ^d   Robinson, John A ^e   Genton, Blaise ^a   Mazier, Dominique ^b   Zurbriggen, Rinaldo ^c   Pluschke, Gerd ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Pevion Biotech Ltd   (Switzerland)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; PEPTIDE VACCINE; VIROSOME; PROTOZOON ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALARIA; MASS IMMUNIZATION; MONOTHERAPY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SPOROZOITE; VIROSOMAL DELVERY; ADULT; ANIMAL; BIOSYNTHESIS; CONTROLLED CLINICAL TRIAL; CROSS REACTION; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; RANDOMIZED CONTROLLED TRIAL; WESTERN BLOTTING;

ANIMALIA; PLASMODIUM FALCIPARUM;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; BLOTTING, WESTERN; CROSS REACTIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALARIA VACCINES; PLASMODIUM FALCIPARUM; VIROSOMES;

EID: 40449085265     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001278     Document Type: Article

References (34)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217.
2. Clyde DF, Most H, McCarthy VC, Vanderberg JP (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266: 169-177.
3. Targett GA (2005) Malaria vaccines 1983-2005: a full circle? Trends Parasitol 21: 499-503.
4. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up Ora randomised controlled trial. Lancet 366: 2012-2018.
5. Alonso, PL. Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411.
6. Greenwood B (2005) Malaria vaccines. Evaluation and implementation. Acta Trop 93: 298-304.
7. Greenwood BM, Bojang K, Whitty CJ, Targett GA (2005) Malaria. Lancet 365: 1487-1498.
8. Waters A (2006) Malaria: new vaccines for old? Cell 124: 689-693.
9. Good MF (2005) Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 21: 29-34.
10. Tongren JE, Zavala F, Roos DS, Riley EM (2004) Malaria vaccines: if at first you don't succeed. Trends Parasitol 20: 604.
11. Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, et al. (1999) Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. ClinExpImmunol 117: 496.
12. Moreno R, Jiang L, Moehle K, Zurbriggen R, Gluck R, et al. (2001) Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2: 838.
13. Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, et al. (2003) Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. InfectImmun 71: 4749.
14. Preiffer B, Peduzzi E, Moehle K, Zurbriggen R, Gluck R, et al. (2003) A Virosome-Mimotope Approach to Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune Recognition of a Potential Malaria-Vaccine Candidate. AngewChemIntEd Engl 42: 2368.
15. Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, et al. (2007) Structure-Activity-Based Design of a Synthetic Malaria Peptide Eliciting Sporozoite Inhibitory Antibodies in a Virosomal Formulation. Chemistry & Biology 14: 577-587.
16. Okitsu SL, Boato F, Mueller MS, Li DB, Vogel D, et al. (2007) Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47kDa fragment both in sporozoites and merozoites. Peptides.
17. Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, et al. (2005) Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 17: 695-704.
18. Zurbriggen R (2003) Immunostimulating reconstituted influenza virosomes. Vaccine 21: 921.
19. Bisang C, Jiang L, Freund E, Emery F, Bauch C, et al. (1998) Synthesis Conformational Properties, and Immunogenicity of a Cyclic Template-Bound Peptide Mimetic Containing an NPNA Motif from the Circumsporozoite Protein of Plasmodium falciparum. J Am Chem Soc 120: 7439-7449.
20. James S, Moehle K, Renard A, Mueller MS, Vogel D, et al. (2006) Synthesis, Solution-Structure and Immune Recognition of an Epidermal Growth Factor-Like Domain from Plasmodium falciparum Merozoite Surfacc Protein-1 ChemBioChem 7: 1943-1950.
21. Genton B, Pluschke, G, Degen L, Kammer AR, Westerfeld N, et al. (2007). A Randomized Placebo-Controlled, Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers. PLoS ONE 2: e1018.
22. Ferreira MU, Kapin AM (1995) The assessment of antibody, affinity distribution by thiocyanate elution: a simple dose-response approach. JImmunolMethods 187: 297.
23. Silvie O, Rubinstein E, Franctich JF, Prenant M, Belnoue R et al, (2003) Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. NatMed 9: 93.
24. Mota MM, Pradel G, Vanderberg JP, Hafalla JCR, Frevert U, et al. (2001) Migration of Plasmodium Sporozoites Through Cells Before Infection. Science 291: 141.
25. Vanderberg JP, Frevert U (2004) Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. IntJParasitol 34: 991.
26. Mazier D, Mellouk S, Beaudoin RL, Texier B, Druilhe P, et al. (1986) Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro. Science 231: 156-159.
27. Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, et al. (2003) Influenza-virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 21: 925.
28. Bachmann MY, Zinkernagel RM (1997) Neutralizing antiviral B cell responses. Ann. Rev Immunol 15: 235-270.
29. Ghasparian A, Moehle K. Linden A, Robinson JA (2006) Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem Commun (Camb). pp 174-176.
30. Pulendran B, Ahmed R (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-863.
31. McHeyzer-Williams, LJ, NcHeyzer-Williams MG (2005) Antigen-specific memory B cell development. Annual Review of Immunology 23: 487-513.
32. Moorthy VS, Dubovsky F (2005) Progress in development of a vaccine to aid malaria control; Sherman IW, ed, Washington; D.C.: ASM Press.
33. Nevill CG, Some ES, Mung'ala VO, Mutemi W, New L, et al. (1996) Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast, Trop Med Int Health 1: 139-146.
34. Kappe SH, Buscaglia CA, Bergman LW, Coppens I, Nussenzweig V (2004) Apicomplexan gliding motility and host cell invasion: overhauling the motor model. Trends Parasitol 20: 13.